- Patient-Derived Organoid (PDO) Screening Platforms
- 3D Tumor Microenvironment (TME) Co-Culture Systems
- High-Content Imaging for Drug Mechanism Analysis
Preclinical Research Services for Glioma
Contact usGliomas are a heterogeneous group of tumors that arise from glial cells in the central nervous system, accounting for a significant proportion of all primary brain tumors. Their aggressive nature and complex biology present substantial challenges in developing effective therapeutic strategies. Preclinical research is essential for understanding glioma pathophysiology and evaluating potential treatments. At Alfa Cytology, we provide specialized preclinical research services focused on glioma, enabling researchers to conduct high-impact studies that pave the way for clinical advancements.
Our Capabilities
Alfa Cytology offers a comprehensive range of preclinical research services tailored specifically for glioma studies. Our expertise encompasses various aspects of glioma research, including model development, therapeutic testing, and biomarker analysis.
In Vitro/Ex Vivo Models
In Vivo Oncology Models
- Subcutaneous/Orthotopic PatientDerived Xenografts (PDX)
- MetastasisSpecific Models (Liver/Lung Colonization)
- Syngeneic Models for Immunotherapy Evaluation
Pharmacodynamic (PD) Studies
- Tumor Growth Inhibition (TGI) and Regression Analysis
- BiomarkerDriven Efficacy Endpoints (e.g., pERK, Ki67)
- Immune Cell Profiling (TILs, Macrophage Polarization)
Pharmacokinetic (PK) & ADME Profiling
- Plasma/Tissue Drug Concentration Quantification (LCMS/MS)
- Absorption, Distribution, Metabolism, Excretion (ADME) Studies
- PK/PD Modeling for Clinical Dose Projection
Toxicology & Safety Pharmacology
- Acute/Subchronic Toxicity Studies
- OrganSpecific Toxicity Screening (Hepatorenal, Hematologic)
- Immunotoxicity and Cytokine Release Syndrome (CRS) Risk Assessment
Biomarker Discovery & Validation
- Liquid Biopsy Biomarker Panels (ctDNA, CTCs, Exosomes)
- Spatial Transcriptomics for Tumor Heterogeneity Mapping
- AI-Powered Predictive Biomarker Identification
Immuno-Oncology Services
- Humanized Mouse Models (huCD34+, huPBMC)
- CART/TIL Efficacy and Safety Profiling
- Immune Checkpoint Inhibitor Combination Strategies
ADC & Biologic Drug Evaluation
- Linker Stability and Payload Release Kinetics
- Bystander Effect Quantification in Heterogeneous Tumors
- Target Specific Internalization Efficiency Assays
Resistance Mechanism Studies
- Clonal Evolution Tracking via Longitudinal ctDNA Analysis
- CRISPR Screens for Drug Resistance Gene Identification
- Tumor Microenvironment (TME)Mediated Resistance Models
Combination Therapy Development
- Synergy Screening (Chemo/Targeted/Immuno Combinations)
- Sequential vs. Concurrent Dosing Optimization
- Toxicity Overlap and Tolerability Assessment
Advanced Imaging & Data Analytics
- In Vivo Bioluminescence/IVIS Imaging for Metastasis Tracking
- AI-Driven Multi-Omics Data Integration (Genomics, Proteomics, Metabolomics)
- Digital Pathology for Automated Tumor Burden Quantification
Custom Model Development
- CRISPR Engineered Cell Lines (Oncogene Knockin/Knockout)
- Microbiome Humanized Models for Gut Tumor Axis Studies
- Radiation Resistant CRC Models for Combo Therapy Testing
FAQs
What modeling systems best replicate glioma recurrence patterns?
Our tiered approach combines:
- Treatment-resistant PDX lines propagated through ≥5 serial passages
- Radiation-induced genetic drift models (6MV LINAC irradiation)
- TMZ-challenged organoid co-cultures with CAF populations
How is therapeutic efficacy quantified beyond RECIST criteria?
We employ:
- Intravital microscopy for real-time vascular normalization tracking
- MR elastography measuring tumor stiffness changes
- Single-cell RNAseq identifying resistant clone emergence
What distinguishes your in vitro blood-brain barrier models?
Our patented NeuroVascular Unit chips incorporate:
- Astrocyte-pericyte-endothelial tri-cultures under physiological shear stress
- P-glycoprotein functionality validation using rhodamine-123 efflux assays
- TEER measurements exceeding 2000 Ω·cm2 for high-fidelity screening